A Pennsylvania biotechnology company is raising $1.5 million to advance its human antibody cloning technology that it believes has broad applications for the treatment of unmet medical needs such as Alzheimer’s disease, cancer, infectious diseases and bioterror attacks.
In its latest financing round, begun Jan. 4, Immunome has raised $145,000.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Dr. Scott K. Dessain, the founder and chief science officer of Immunome, is an associate professor with the Lankenau Institute for Medical Research in Wynnewood, Pennsylvania.
The CEO of Immunome, Timothy Pelura, is a serial entrepreneur in life sciences with more than 35 years of experience in the pharmaceutical, biotechnology and medical device sectors, according to the company’s website. He has served as CEO of Promedior, a biotech company that developed therapeutics for the treatment of fibrotic disorders and diseases. He also worked at Kereos, Provasis Therapeutics, Neuron Therapeutics and Alliance Pharmaceutical Corp., according to the company’s website.
Among its investors are BioAdvance, the biotechnology greenhouse of Southeastern Pennsylvania and I Wistar Morris III, an investment banker, along with private investors.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
